TABLE 4.
Average rectum dose from 12 prostate cancer VMAT plans for RP model (RP), all planners (ALL), each planner group (G1, G2, and G3), and clinical plans (CL).
| Organ | Dose constraints | Model | Mean ± SD (%) | p‐value |
|---|---|---|---|---|
| Rectum | V75Gy < 15% | RP | 11.41 ± 2.1 | Ref |
| ALL | 12.33 ± 1.5 | 0.034 | ||
| G1 | 12.05 ± 1.7 | 0.049 | ||
| G2 | 12.32 ± 1.4 | 0.034 | ||
| G3 | 12.44 ± 1.6 | 0.028 | ||
| CL | 12.06 ± 2.3 | 0.042 | ||
| V70Gy < 25% | RP | 15.03 ± 2.5 | Ref | |
| ALL | 16.63 ± 1.8 | 0.008 | ||
| G1 | 16.41 ± 2.1 | 0.015 | ||
| G2 | 16.82 ± 1.7 | 0.004 | ||
| G3 | 16.53 ± 1.9 | 0.028 | ||
| CL | 16.16 ± 2.8 | 0.039 | ||
| V65Gy < 35% | RP | 18.21 ± 2.4 | Ref | |
| ALL | 20.44 ± 2.1 | 0.006 | ||
| G1 | 20.22 ± 2.5 | 0.008 | ||
| G2 | 20.24 ± 2.3 | 0.004 | ||
| G3 | 20.81 ± 2.1 | 0.019 | ||
| CL | 19.99 ± 2.5 | 0.005 | ||
| V60Gy < 50% | RP | 21.32 ± 3.8 | Ref | |
| ALL | 24.25 ± 3.3 | 0.005 | ||
| G1 | 23.81 ± 2.8 | 0.005 | ||
| G2 | 24.84 ± 2.7 | 0.005 | ||
| G3 | 24.13 ± 3.1 | 0.012 | ||
| CL | 23.96 ± 2.9 | 0.005 |